SCHEMBL3016720

SCHEMBL3016720

Cc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4ccccc4Br)CC3)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
ALDH1A1 P00352 4/20 0.42
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GBA1 P04062 2/20 0.41
MAPK1 P28482 1/20 0.41
PKM P14618 1/20 0.39
TP53 P04637 1/20 0.38
DNM1L O00429 1/20 0.37
KDM4E B2RXH2 2/20 0.37
POLB P06746 1/20 0.37
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3001890 0.92 GBA1 (0.42) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3012745 0.90 LMNA (0.43) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3010327 0.90 MEN1 (0.43) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3009631 0.89 GBA1 (0.43) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3013120 0.89 GBA1 (0.48) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3007742 0.89 GBA1 (0.41) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3014169 0.88 MAPT (0.48) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3015990 0.87 TSHR (0.42) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3016917 0.86 TRPV4 (0.37) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3007459 0.86 ALDH1A1 (0.48) MAPTALDH1A1LMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.